Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Equity Average: 2024-2025

Historic Equity Average for Inhibrx Biosciences (INBX) over the last 1 years, with Sep 2025 value amounting to $52.7 million.

  • Inhibrx Biosciences' Equity Average fell 73.51% to $52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.7 million, marking a year-over-year decrease of 73.51%. This contributed to the annual value of $88.5 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Inhibrx Biosciences reported Equity Average of $52.7 million as of Q3 2025, which was down 35.34% from $81.5 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Equity Average high stood at $198.9 million for Q3 2024, and its period low was $52.7 million during Q3 2025.
  • Moreover, its 2-year median value for Equity Average was $114.0 million (2025), whereas its average is $120.6 million.
  • Data for Inhibrx Biosciences' Equity Average shows a maximum YoY plummeted of 73.51% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Inhibrx Biosciences' Equity Average stood at $156.0 million in 2024, then plummeted by 73.51% to $52.7 million in 2025.
  • Its Equity Average was $52.7 million in Q3 2025, compared to $81.5 million in Q2 2025 and $114.0 million in Q1 2025.